Shares of Q32 Bio Inc. (NASDAQ:QTTB – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eight ...

Q32 Bio Inc. (NASDAQ:QTTB – Get Free Report) was the target of a large growth in short interest in the month of December. As ...

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Q32 Bio (QTTB – Research Report), with a price target of $20.00. The company’s shares closed yesterday at $24.41.

Fintel reports that on December 12, 2024, Guggenheim downgraded their outlook for Q32 Bio (NasdaqGM:QTTB) from Buy to Neutral. Analyst Price Forecast Suggests 1,981.80% Upside As of December 3 ...

Fintel reports that on December 11, 2024, Raymond James downgraded their outlook for Q32 Bio (NasdaqGM:QTTB) from Strong Buy to Outperform. Analyst Price Forecast Suggests 260.75% Upside As of ...

Piper Sandler analyst Christopher Raymond maintained a Buy rating on Q32 Bio (QTTB – Research Report) today and set a price target of $20.00. The company’s shares closed yesterday at $24.41.

Shares of Q32 Bio QTTB lost nearly 77% yesterday after it reported mixed results from two separate phase IIa studies evaluating its investigational drug bempikibart one in atopic dermatitis (AD or ...

Investing.com - Homology Medicines (NASDAQ: FIXX) reported first quarter EPS of $-0.600, $0.11 worse than the analyst estimate of $-0.492. Revenue for the quarter ...

Q32 Bio, Inc. (NASDAQ:QTTB), a biotechnology company focused on developing therapies for inflammatory diseases, has recently experienced significant shifts in its market outlook following ...

Price Action: QTTB stock is down 67.1% at $8.04 at last check Wednesday.

(RTTNews) - Shares of Q32 Bio (QTTB) are down 65%, following disappointing results from its SIGNAL-AD clinical trial. SIGNAL-AD is a Phase 2a clinical trial evaluating lead drug candidate ...